On May 7, Cancer Commons founder Marty Tenenbaum hosted a panel in The Scientist‘s three-part webinar series Decoding DNA: New Twists and Turns. A summary of the webinar was featured in the June issue of The Scientist: The Scientist June 2013 JMT Webinar. Watch Dr. Tenenbaum and other experts discuss The Impact of Personalized Medicine:
“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.
Jay M. (‘Marty’) Tenenbaum, Ph.D., Chairman and Founder, Cancer Commons
Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program
Geoffrey S. Ginsburg, MD, PhD, Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy Executive Director, Center for Personalized Medicine Duke Medicine, Professor of Medicine and Pathology Duke University Medical Center
Abhijit ‘Ron’ Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson”